PRJNA859919
Analysis and Therapeutic Targeting of the EP300 and CREBBP Acetyltransferases in Anaplastic Large Cell Lymphoma and Hodgkin Lymphoma
(1): RNA-seq results of ALCL cell lines (DEL, Karpas299, and MAC1) and Hodgkin lymphoma cell lines (KMH2 and L1236) treated with EP300/CBP HAT inhibitor A-485 and bromodomain inhibitor CPI-637. (2): RNA-seq results of ALCL cell line (DEL) transduced with CTRL, EP300, or CREBBP sgRNAs.